About
Dr Neil Thomas joined Ventac Partners in March 2012. Dr. Neil Thomas has worked in the protection and commercial exploitation of academic and industrial intellectual property in the biotechnology sector since 1997, within both legal and business environments. Dr. Thomas brings extensive experience in company formation, patent drafting, patent portfolio management, business development, licensing and technology exploitation. Prior to joining Ventac Partners, Dr. Thomas was Director of Business Development & IP at Genetrix, a biotechnology fund in Madrid, Spain. Dr. Thomas was responsible for IP, business development, licensing, and fund raising assistance for the group's 10 companies, including the IP and licensing elements of two €27M VC funding rounds for Cellerix SA (now TiGenix NV) and a large product licensing deal for that same company with Axcan Pharma, Inc. Dr. Thomas was also responsible for the successful sale of Genetrix group company Imbiosis SL to R-Biopharm AG. He establi
Position in the VCSift Database
- • 14 investors at Ventac Partners are tracked.
- • 2,531 investors hold the Partner role in VCSift. Neil Thomas is one of them.
- • 930 investors are based in Madrid, Madrid, Spain.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Madrid, Spain
Contact Information
Find more investors like Neil
Search Investors